

- Kherabi Y., Pedersen O., Lange C., Bénézit F., Chesov D., Codecasa L., Dudnyk A., Kiria N., Konstantynovska O., Marigot-Outtandy D., Panciu T., Poignon C., Sasi S., Schaub D., Solodovnikova V., Vasiliauskaitė L., Yeghiazaryan L., Günther G., Guglielmetti L., Aubry A., Vasiliu A., McLaughlin A., Lange C., Poignon C., Cirillo D., Podlekareva D., Davidavičienė E., Fumagalli G., Troia G., Günther G., Motta I., Jonsson J., Robert J., Eimer J., Kuska L., Guglielmetti L., Skowroński M., Fitzgibbon M., Revest M., Veziris N., Pedersen O., Konstantynovska O., Opota O., Viiklepp P., Coriu R., Tunesi S., Sasi S., Skogmar S., Bjerrum S., Togonidze T., Lillebaek T., Pourcher V., Le V., and Kherabi Y., 2025, Treatment outcomes of extensively drug-resistant tuberculosis in Europe: a retrospective cohort study, *The Lancet Regional Health-Europe*, 56: 101380.  
<https://doi.org/10.1016/j.lanepe.2025.101380>
- Kumar B., Sharma D., Venkatesan K., and Bisht D., 2025, Proteomic analysis of drug-resistant mycobacterium tuberculosis clinical isolates under aminoglycoside drug pressure, *Current Microbiology*, 82(8): 361.  
<https://doi.org/10.1007/s00284-025-04341-8>
- Li B., Wen F., and Wang Z., 2022, Correlation between polymorphism of vitamin D receptor TaqI and susceptibility to tuberculosis, *Medicine*, 101(16): e29127.  
<https://doi.org/10.1097/md.00000000000029127>
- Li C., Liang S., Wang X., Lui S., and Wang C., 2025, Risk factors associated with morbidity and unfavorable treatment outcome in drug-resistant pulmonary tuberculosis: a case-control study, *Precision Clinical Medicine*, 8(2): pbaf008.  
<https://doi.org/10.1093/pccmedi/pbaf008>
- Liang D., Song Z., Liang X., Qin H., Huang L., Ye J., Lan R., Luo D., Zhao Y., and Lin M., 2023, Whole genomic analysis revealed high genetic diversity and drug-resistant characteristics of mycobacterium tuberculosis in Guangxi China, *Infection and Drug Resistance*, 16: 5021-5031.  
<https://doi.org/10.2147/idr.s410828>
- Liebenberg D., Gordhan B., and Kana B., 2022, Drug resistant tuberculosis: implications for transmission diagnosis and disease management, *Frontiers in Cellular and Infection Microbiology*, 12: 943545.  
<https://doi.org/10.3389/fcimb.2022.943545>
- Liu C., Wu L., Lin C., Wu H., Liu K., and Lee S., 2024, Association of tuberculosis risk with genetic polymorphisms of the immune checkpoint genes PDCD1 CTLA-4 and TIM3, *PLOS ONE*, 19(5): e0303431.  
<https://doi.org/10.1371/journal.pone.0303431>
- Liu Q., Yang D., Qiu B., Martinez L., Ji Y., Song H., Li Z., and Wang J., 2021, Drug resistance gene mutations and treatment outcomes in MDR-TB: a prospective study in Eastern China, *PLoS Neglected Tropical Diseases*, 15(1): e0009068.  
<https://doi.org/10.1371/journal.pntd.0009068>
- Lv H., Zhang X., Zhang X., Bai J., You S., Li X., Li S., Wang Y., Zhang W., and Xu Y., 2024, Global prevalence and burden of multidrug-resistant tuberculosis from 1990 to 2019, *BMC Infectious Diseases*, 24(1): 243.  
<https://doi.org/10.1186/s12879-024-09079-5>
- Michalik M., Lorenc T., Marcinkowski K., Muras M., Mikszta N., Mikszta J., Kantor K., and Marcinkowska J., 2025, Advances and prospects for treatment strategies of drug-resistant tuberculosis: a review, *GMS Hygiene and Infection Control*, 20: 33.  
<https://doi.org/10.3205/dgkh000562>
- Miirio E., Olum R., and Baluku B., 2023, Clinical features resistance patterns and treatment outcomes of drug-resistant extra-pulmonary tuberculosis: a scoping review, *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases*, 33: 100390.  
<https://doi.org/10.1016/j.jctube.2023.100390>
- Motta I., Boeree M., Chesov D., Dheda K., Günther G., Horsburgh C., Kherabi Y., Lange C., Lienhardt C., McIlleron H., Paton N., Stagg H., Thwaites G., Udvardi Z., Van Crevel R., Velásquez G., Wilkinson R., and Guglielmetti L., 2023, Recent advances in the treatment of tuberculosis, *Clinical Microbiology and Infection*, 30(9): 1107-1114.  
<https://doi.org/10.1016/j.cmi.2023.07.013>
- Samad N., Wardak G., Batool F., Kenoosh H., Opara N., Anwar N., Doraghi K., and Bashir M., 2024, Drug resistance pattern prevalence and risk factors for resistance to second line anti-tuberculosis drugs in Balochistan Pakistan, *Romanian Journal of Infectious Diseases*, 27(3): 237.  
<https://doi.org/10.37897/rjid.2024.3.12>
- Soedarsono S., Mertaniasih N., Kusmiati T., Permatasari A., Ilahi W., and Anggraeni A., 2023, Characteristics of previous tuberculosis treatment history in patients with treatment failure and the impact on acquired drug-resistant tuberculosis, *Antibiotics*, 12(3): 598.  
<https://doi.org/10.3390/antibiotics12030598>
- Song Z., Liu C., He W., Pei S., Liu D., Cao X., Wang Y., He P., Zhao B., Ou X., Xia H., Wang S., and Zhao Y., 2023, Insight into the drug-resistant characteristics and genetic diversity of multidrug-resistant mycobacterium tuberculosis in China, *Microbiology Spectrum*, 11(5): e01324-23.  
<https://doi.org/10.1128/spectrum.01324-23>
- Varshney K., Anaele B., Molaei M., Frasso R., and Maio V., 2021, Risk factors for poor outcomes among patients with extensively drug-resistant tuberculosis (XDR-TB): a scoping review, *Infection and Drug Resistance*, 14: 5429-5448.  
<https://doi.org/10.2147/idr.s339972>
- Venkatesh K., Usharani B., Anbazhagi M., Rakesh G., and Muthuraj M., 2021, Risk factors and treatment outcome analysis associated with second-line drug-resistant tuberculosis, *Journal of Respiration*, 2(1): 1-12.  
<https://doi.org/10.3390/jor2010001>
- Wang J., Wang M., Li Z., Wu X., Zhang X., Julius A., Zhong H., Huang X., Chen M., Tan H., and Yi H., 2021, Impact of PD-1 gene polymorphism and its interaction with tea drinking on susceptibility to tuberculosis, *Epidemiology and Infection*, 149: e29.  
<https://doi.org/10.1017/s0950268821000042>